Thus, blockade of Siglec-10+ TAMs has observed improved CD8+ T cell cytotoxicity and immunotherapy in patients with hepatocellular carcinoma (HCC) [124]. The gene discussed is CD8A; the disease is hepatocellular carcinoma.